


IN THE CLAIMS:

1. (original) A pharmaceutical composition in oral or systemic dosage form for administration to a mammalian patient comprising an effective amount of a compound to inhibit angiogenesis in said patient said compound having the structure:



wherein R^1 and R^2 are each independently selected from a C_1 to C_{20} saturated or unsaturated linear, cyclic or branch-chained substituted or unsubstituted hydrocarbon group, or a pharmaceutically acceptable salt thereof.

2. (Previously presented) The composition according to claim 1, wherein R^1 and R^2 are each independently a C_1 to C_{11} hydrocarbon group.

3. (Previously presented) The composition according to claim 1, wherein R^1 or R^2 is an ester group.

4. (Previously presented) The composition according to claim 1 wherein R^1 or R^2 contains an unsaturated group.

5. (Previously presented) The composition according to claim 1 wherein R^1 or R^2 is a straight or branch-chained alkyl or alkenyl group, a cyclic alkyl group, an alkylphenyl group, alkenyl phenyl group, alkyl ester alkanoate or alkyl ester alkenoate group.

6. (Previously presented) The composition according to claim 1 wherein R^1 and R^2 are each independently selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, 4-methylpentyl, 5-methylhexyl, cyclopentyl, cyclohexyl, vinyl,

propenyl, butenyl, pentenyl, hexenyl, heptenyl, 3-methylbutenyl, 5-methylhexenyl, benzyl, ethylbenzene, propylbenzene, ethyl propanoate and ethyl propenoate.

7. (Previously presented) The composition according to claim 1 wherein R¹ is a methyl group.

8. (Previously presented) A method of treating a tumor or cancer in a patient comprising administering to said patient an effective amount of the pharmaceutical composition according to any of claims 1-7 to said patient.

9-14. (cancelled)

15. (Presently amended) A method of treating a tumor or cancer in a patient comprising administering to said patient an effective amount of the pharmaceutical composition according to any of claims 1-7 wherein said tumor is selected from the group consisting of neurofibromatosis, tuberous sclerosis, hemangiomas and lymphangiogenesis and said cancer is selected from the group consisting of cervical, anal and oral cancers, eye or ocular cancer, stomach, colon, bladder, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, renal, brain/cns, head and neck, throat, cutaneous malignancy, skin melanoma, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's Sarcoma, Kaposi's Sarcoma, basal cell carcinoma and squamous cell carcinoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, angiosarcoma, hemangioendothelioma, Wilms Tumor, neuroblastoma, mouth/pharynx, esophageal, larynx, kidney and lymphoma.

16-21. Cancelled.

22-23. Cancelled.

24-28. Cancelled.

29. Cancelled.

30-37. Cancelled.

38. (New) A method according to claim 8 wherein said tumor or cancer is a cutaneous malignancy.

39. (New) A method according to claim 15 wherein said tumor or cancer is a cutaneous malignancy.